Citations

Mayo Clinic

Clear

12583 citation(s) found for "Vu, John A".

Gemcitabine, Cisplatin, and Radiotherapy for Patients With Locally Advanced Pancreatic Adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942
Haddock, Michael G. , Swaminathan, Revathi, Foster, Nathan R. , Hauge, Mark D., Martenson, James A., Camoriano, John , Stella, Philip J., Tenglin, Richard C., Schaefer, Paul, Moore, Dennis F., Alberts, Steven R.

Journal of Clinical Oncology | June 18, 2007 | Volume: 25 | Issue: 18 | Pages: 2567-2572

10.1200/jco.2006.10.2111 | PMID 17577035 Get It

Purpose A phase II study was conducted to determine the efficacy and toxicity of radiotherapy with concomitant gemcitabine and cisplatin for patients with locally advanced pancreatic adenocarcinoma. Patients and Methods Forty-eight patients with locally advanced pancreatic adenocarcinoma received gemcitabine (30 mg/m2) and cisplatin (10 mg/m2) twice weekly during the first 3 weeks of radiotherapy. The radiation dose to the primary tumor and regional nodes was 45 Gy in 25 fractions, and the gross tumor volume received an additional 5.4 Gy in three fractions. Four weeks after radiotherapy, patients received gemcitabine (1,000 mg/m2) once weekly every 3 of 4 weeks for a 12-week period. The primary end point was survival at 12 months. Secondary end points were time to progression, toxicity, and quality of life. Results Survival at 1 year was 40% for 47 eligible patients. The median survival was 10.2 months. Confirmed responses were observed for 8.5% (two partial, two complete), and median time to progression was 7.3 months. Grade 4 or higher toxicity was observed for 31% and consisted primarily of hematologic and GI toxicity. There was a trend toward improved overall quality of life, measured by the Symptom Distress Scale (P = .06), with significant improvements in domains of insomnia, pain, and outlook. Conclusion The combination of radiotherapy, gemcitabine, and cisplatin was well tolerated. Survival results were similar to those achieved with other treatment regimens for patients with locally advanced pancreatic cancer but did not meet our predefined criteria for additional evaluation of this regimen.
High Sensitivity of In Vivo Detection of Gold Nanorods Using a Laser Optoacoustic Imaging System
Eghtedari, Mohammad , Oraevsky, Alexander A. , Copland, John A. , Kotov, Nicholas A. , Conjusteau, André, Motamedi, Massoud

Nano Letters | June 15, 2007 | Volume: 7 | Issue: 7 | Pages: 1914-1918

10.1021/nl070557d | PMID 17570730 Get It

The Compartments of the Foot: A 3-Tesla Magnetic Resonance Imaging Study with Clinical Correlates for Needle Pressure Testing
Reach, John S., Amrami, Kimberly K. , Felmlee, Joel P. , Stanley, David , Alcorn, Joseph, Turner, Norman S.

Foot & Ankle International | June 8, 2007 | Volume: 28 | Issue: 5 | Pages: 584-594

10.3113/fai.2007.0584 | PMID 17559766 Get It

Background: Reliable measurement of subfascial pressures represents an essential part of compartment syndrome management. To date, there is neither consensus on the number or location of foot compartments, nor a standardized protocol for needle placement. The purpose of this study was to devise a new system using 3-Tesla MRI that assesses the number and location of these compartments. Methods: To document the specific location of foot compartments, high resolution 3-Tesla MRI (General Electric, Milwaukee, WI) was coupled with a dedicated transmit-receive high signal-to-noise foot/ankle coil (IGC-Medical Advances, Milwaukee, WI). Individual compartments were highlighted and mapped to T1-weighted MRI. Three-dimensional image analysis allowed standardized needle placement recommendations. Results: Six feet from healthy volunteers were imaged. From these, ten compartments were described: (1) medial, (2) central superficial, (3) central deep (adductor), (4) lateral, (5–8) interossei, (9) calcaneal, and (10) skin. Optimal needle placement and depth were identified. Conclusions: The proposed system allowed us to assess the number and location of foot compartments. Computer image analysis enabled us to define exact points for needle insertion and depth of penetration for accurate pressure monitoring.
Hip Arthroscopy: An Emerging Gold Standard
Beaulé, Paul E. , Clohisy, John C. , Schoenecker, Perry L. , Kim, Young‐Jo , Millis, Michael B. , Trousdale, Robert T. , Beaulé, Paul E

Arthroscopy | June 8, 2007 | Volume: 23 | Issue: 6 | Pages: 682-682

10.1016/j.arthro.2007.03.007 | PMID 17560490 Get It

P‐020: Regional gray matter reductions in Alzheimer's dementia and amnestic mild cognitive impairment: Preliminary findings from the Alzheimer's disease neuroimaging initiative using voxel‐based morphometry
Alexander, Gene E. , Reiman, Eric M. , Aschenbrenner, Melaney, Hanson, Krista D., Kornak, John , Schuff, Norbert, Weiner, Michael W. , Chen, Kewei , Merkley, Tricia L. , Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Thompson, Paul M. , Jack, Clifford R.

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_1 | Pages: No page available

10.1016/j.jalz.2007.04.236 Get It

O1–04–04: The Alzheimer's disease neuroimaging initiative: Progress report
Weiner, Michael W. , Thal, Leon J., Petersen, Ronald C. , Jagust, William J. , Trojanowski, John Q., Shaw, Leslie M. , Gamst, Anthony, Jack, Clifford R. , Trojanowski, John Q., Toga, Arthur W. , Beckett, Laurel

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.080 Get It

Association of Integrin α2 Gene Variants with Ischemic Stroke
Matarín, Mar, Brown, W. Mark , Hardy, John , Rich, Stephen S. , Singleton, Andrew , Brown, Robert D., Brott, Thomas G. , Worrall, Bradford B. , ISGS, SWISS, Groups, MSGD Study, Meschia, James F. , ISGS, SWISS, Groups, MSGD Study, Rich, Stephen S , Hardy, John

Journal of Cerebral Blood Flow & Metabolism | May 30, 2007 | Volume: 28 | Issue: 1 | Pages: 81-89

10.1038/sj.jcbfm.9600508 | PMID 17534386 Get It

Genetic variants in the gene encoding integrin α2 ( ITGA2) have been reported to be associated with an increased risk for ischemic stroke. The purpose of this study was to investigate the association between haplotype-tagging single-nucleotide polymorphisms (tSNPs) in ITGA2 and risk of ischemic stroke in a collection of North American stroke cases and controls. The study included 484 cases and 263 controls. Thirteen tSNPs were genotyped. Association tests at and across each tSNP were performed, including haplotype association analysis. Secondary analyses considered stroke subtypes on the basis of Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. We observed significant association between tSNP rs3756541 (additive model, odds ratio (OR), 1.49; 95% confidence interval (CI), 1.11 to 2.04; P = 0.009) and disease and a trend toward association at rs2303124 (recessive model, OR, 1.56; 95% CI, 1.05 to 2.33; P = 0.03). These associations remained significant in the haplotype analyses. The associated tSNPs did not distinguish stroke etiology after application of TOAST criteria. Our results suggest that genetic variability within ITGA2 may confer risk for ischemic stroke independent of conventional risk factors. These results provide additional support for a role for platelet receptor genes in the pathogenesis of ischemic stroke of diverse subtypes.
Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Δ51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
Goel, Apollina, Carlson, Stephanie K., Classic, Kelly, Greiner, Suzanne , Naik, Shruthi , Power, Anthony, Bell, John C. , Russell, Stephen J.

Blood | May 22, 2007 | Volume: 110 | Issue: 7 | Pages: 2342-2350

10.1182/blood-2007-01-065573 | PMID 17515401 Get It

Multiple myeloma is a radiosensitive malignancy that is currently incurable. Here, we generated a novel recombinant vesicular stomatitis virus [VSV(Δ51)-NIS] that has a deletion of methionine 51 in the matrix protein and expresses the human sodium iodide symporter (NIS) gene. VSV(Δ51)-NIS showed specific oncolytic activity against myeloma cell lines and primary myeloma cells and was able to replicate to high titers in myeloma cells in vitro. Iodide uptake assays showed accumulation of radioactive iodide in VSV(Δ51)-NIS–infected myeloma cells that was specific to the function of the NIS transgene. In bg/nd/xid mice with established subcutaneous myeloma tumors, administration of VSV(Δ51)-NIS resulted in high intratumoral virus replication and tumor regression. VSV-associated neurotoxicity was not observed. Intratumoral spread of the infection was monitored noninvasively by serial gamma camera imaging of 123I-iodide biodistribution. Dosimetry calculations based on these images pointed to the feasibility of combination radiovirotherapy with VSV(Δ51)-NIS plus 131I. Immunocompetent mice with syngeneic 5TGM1 myeloma tumors (either subcutaneous or orthotopic) showed significant enhancements of tumor regression and survival when VSV(Δ51)-NIS was combined with 131I. These results show that VSV(Δ51)-NIS is a safe oncolytic agent with significant therapeutic potential in multiple myeloma.
Direct Submentoplasty for Neck Rejuvenation
Bitner, John B., Farrior, Richard T., Cook, Ted A., Friedman, Oren A

Archives of Facial Plastic Surgery | May 21, 2007 | Volume: 9 | Issue: 3 | Pages: 194-200

10.1001/archfaci.9.3.194 | PMID 17515496 Get It

Facial plastic surgeons commonly see patients with submental laxity and an excess of skin and fat in the upper neck. This has colloquially been called the “turkey gobbler” deformity. In some cases, this deformity is the patient's only aesthetic concern, and full face-lift surgery is not desired. In this study, we reviewed the English-language peer-reviewed literature for descriptions of direct excisional submentoplasty techniques. Various designs for skin excision and wound closure have been used by surgeons over the past several decades. This article summarizes the surgical technique as well as the advantages and disadvantages of each method. Furthermore, we propose an approach that incorporates many of the other designs but to our knowledge has not been described previously in the peer-reviewed literature. An understanding of these numerous approaches will better enable facial plastic surgeons to appropriately address and correct patient aesthetic concerns.
EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity
Vikis, Haris G., Sato, Mitsuo , James, Michael A. , Wang, Daolong, Wang, Yian , Wang, Min , Jia, Dongmei , Liu, Yan , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F. , Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Seminara, Daniela, Viswanathan, Avinash, Govindan, Ramaswamy , Anderson, Marshall W., You, Ming , Amos, Christopher I. , Andrade, Mariza de , Yang, Ping , Minna, John Dorrance , Wilson, Richard K , Pinney, Susan M , Govindan, Ramaswamy

Cancer Research | May 18, 2007 | Volume: 67 | Issue: 10 | Pages: 4665-4670

10.1158/0008-5472.can-07-0217 | PMID 17510392 Get It

Abstract The use of tyrosine kinase inhibitors (TKI) has yielded great success in treatment of lung adenocarcinomas. However, patients who develop resistance to TKI treatment often acquire a somatic resistance mutation (T790M) located in the catalytic cleft of the epidermal growth factor receptor (EGFR) enzyme. Recently, a report describing EGFR-T790M as a germ-line mutation suggested that this mutation may be associated with inherited susceptibility to lung cancer. Contrary to previous reports, our analysis indicates that the T790M mutation confers increased Y992 and Y1068 phosphorylation levels. In a human bronchial epithelial cell line, overexpression of EGFR-T790M displayed a growth advantage over wild-type (WT) EGFR. We also screened 237 lung cancer family probands, in addition to 45 bronchoalveolar tumors, and found that none of them contained the EGFR-T790M mutation. Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer. [Cancer Res 2007;67(10):4665–70]